Microglia Alzheimer’s sleep loss research has taken a decisive step forward: a team at the University of Kentucky has shown that the brain’s own immune cells, not amyloid plaques or dying neurons, are the primary cause of sleep disruption in Alzheimer’s disease. By temporarily removing those cells in animal models, the researchers restored more than two hours of sleep per night, and published their findings in the journal Alzheimer’s & Dementia.
Microglia and Alzheimer’s Sleep Loss: A New Target
The study was led by Shannon L. Macauley, an associate professor of physiology in the UK College of Medicine, and first author Nicholas J. Constantino, a recent UK doctoral graduate. Their work reframes what has long been considered a straightforward consequence of neurodegeneration.
Sleep disturbance is not a peripheral symptom of Alzheimer’s. According to Medical Daily, between 25 and 45 per cent of Alzheimer’s patients are affected by sleep loss, making it one of the condition’s most prevalent and debilitating features. Until now, the received view was that this disruption stemmed from the physical accumulation of amyloid plaques or the gradual death of neurons. The Kentucky team’s findings challenge both assumptions.
‘Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia,’ Macauley said. ‘Microglia are immune cells that, when they respond to plaques, kick off this elaborate cascade of inflammation, as if the microglia are partying all night, and keeping the brain awake.’
How the Research Was Conducted
To separate the effects of Alzheimer’s from ordinary ageing, the team used two groups of mice: those with a genetic predisposition to develop amyloid plaques and ‘wild-type’ mice that aged normally. As TechTimes reports, the genetically modified animals were APPswe/PSEN1dE9 mice, a model that develops amyloid plaques similar to those found in human Alzheimer’s disease. The researchers studied both groups at six months, when plaques first emerge, and at 18 months, representing late-stage disease.
To test their hypothesis, the team administered a drug called Pexidartinib (PLX3397) for 14 days. The drug works by blocking the colony-stimulating factor 1 receptor (CSF1R), a survival signal that microglia depend on. With that signal cut off, 87 per cent of the brain’s immune cells were temporarily depleted, allowing the researchers to observe what happened to sleep in their absence.
The answer was unambiguous. Mice with Alzheimer’s pathology regained more than two hours of sleep per night. Their restorative non-rapid eye movement (NREM) sleep bouts grew longer, giving them more opportunities to transition into healthy dreaming sleep. Crucially, this recovery occurred without any reduction in amyloid plaque levels, which suggests the inflammatory response is a reversible cause of sleep loss that can be addressed independently of the plaques themselves.
The team also applied a mathematical algorithm to separate the brain’s electrical activity into periodic waves and aperiodic background noise, giving them a finer view of how the brain behaves during rest and wakefulness.
A Ceiling Effect and a Cleaning Cycle
One of the more counterintuitive findings concerned the relationship between plaque burden and sleep disruption. ‘I expected that as plaque burden became more severe, sleep disruption would also worsen,’ Constantino said. ‘The disruptions in sleep and cortical EEG activity that occur at six months, when plaques first emerge, did not worsen by 18 months, despite more than double the amount of plaque burden.’
The team describes this as a ceiling effect: the initial immune storm triggered by early plaques appears to set the level of sleep disruption, and that level holds even as plaques continue to accumulate. The implication is that early intervention, before the immune response has run its course, may matter more than the total volume of plaques.
The study also drew a clear line between normal ageing and disease. Normal ageing selectively reduces REM sleep. Alzheimer’s pathology targets NREM sleep instead: the restorative stage responsible for physical repair, learning, memory consolidation, and what Macauley describes as ‘washing out the toxins of the day.’ Losing that stage, she argues, removes the brain’s primary cleaning cycle and may create a feed-forward loop that drives further damage.
What Comes Next
Macauley’s lab is not resting on depletion as a clinical strategy. Removing 87 per cent of the brain’s immune cells is a research tool, not a treatment. The team is now exploring whether existing medications, including the diabetes drug Metformin and the anti-seizure drug Stiripentol, could calm overactive microglia without eliminating them, by changing how those cells use fuel.
The study was partly funded by grants from the NIH, the Cure Alzheimer’s Fund, and The CART Fund. Beyond its therapeutic implications, the research points to a practical monitoring tool. The team believe EEG could serve as ‘a readily accessible, affordable and longitudinal biomarker of Alzheimer’s disease.’ Portable EEG systems, Macauley said, could allow clinicians to screen patients in their home environments, before any need for expensive or invasive tests at specialist centres.
Macauley’s lab plans to publish results from the Metformin and Stiripentol investigations as that work progresses. The University of Kentucky team’s next stated aim is to establish whether the sleep recovery observed in animal models can be replicated in humans.
